Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains

Journal of Virology

Volumn 88, Issue 2, 2014, Pages 1125-1139

  Chen, Weizao ^a   Feng, Yang ^a   Prabakaran, Ponraj ^a   Ying, Tianlei ^a   Wang, Yanping ^a   Sun, Jianping ^b   Macedo, Camila D S ^c,d   Zhu, Zhongyu ^a   He, Yuxian ^b   Polonis, Victoria R ^d   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF PATHOGEN BIOLOGY   (China)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; ENFUVIRTIDE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HYBRID PROTEIN; NEUTRALIZING ANTIBODY;

ARTICLE; BINDING SITE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; THERMOSTABILITY; VIRUS NEUTRALIZATION;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CROSS REACTIONS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; SINGLE-DOMAIN ANTIBODIES;

EID: 84891697346     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02566-13     Document Type: Article

References (71)

1. Dimitrov DS, Willey RL, Martin MA, Blumenthal R. 1992. Kinetics of HIV-1 interactions with sCD4 and CD4+ cells: implications for inhibition of virus infection and initial steps of virus entry into cells. Virology 187:398-406. http://dx.doi.org/10.1016/0042-6822(92)90441-Q.
2. Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ. 1987. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 238:1704-1707. http://dx.doi.org/10.1126/science.3500514.
3. Kahn JO, Allan JD, Hodges TL, Kaplan LD, Arri CJ, Fitch HF, Izu AE, Mordenti J, Sherwin JE, Groopman JE, Volberding PA. 1990. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: a phase 1 study. Ann. Intern. Med. 112:254-261.
4. Schacker T, Collier AC, Coombs R, Unadkat JD, Fox I, Alam J, Wang JP, Eggert E, Corey L. 1995. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9:145-152.
5. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E, et al. 1990. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: a phase I-II escalating dosage trial. Ann. Intern. Med. 112:247-253.
6. Langner KD, Niedrig M, Fultz P, Anderson D, Reiner G, Repke H, Gelderblom H, Seed B, Hilfenhaus J, Zettlmeissl G. 1993. Antiviral effects of different CD4-immunoglobulin constructs against HIV-1 and SIV: immunological characterization, pharmacokinetic data and in vivo experiments. Arch. Virol. 130:157-170.
7. Meng TC, Fischl MA, Cheeseman SH, Spector SA, Resnick L, Boota A, Petrakis T, Wright B, Richman DD. 1995. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:152-160.
8. Chamow SM, Duliege AM, Ammann A, Kahn JO, Allen JD, Eichberg JW, Byrn RA, Capon DJ, Ward RH, Ashkenazi A. 1992. CD4 immunoadhesins in anti-HIV therapy: new developments. Int. J. Cancer Suppl. 7:69-72.
9. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, Hasel KW, Gauduin MC, Koup RA, McDougal JS, et al. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 11:533-539. http://dx.doi.org/10.1089/aid.1995.11.533.
10. Fletcher CV, DeVille JG, Samson PM, Moye JH, Jr, Church JA, Spiegel HM, Palumbo P, Fenton T, Smith ME, Graham B, Kraimer JM, Shearer WT. 2007. Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children. J. Allergy Clin. Immunol. 119:747-750. http://dx.doi.org/10.1016/j.aci.2006.10.045.
11. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC. 2004. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. 48:423-429. http://dx.doi.org/10.1128/AAC.48.2.423-429.2004.
12. Chen W, Feng Y, Gong R, Zhu Z, Wang Y, Zhao Q, Dimitrov DS. 2011. Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J. Virol. 85:9395-9405. http://dx.doi.org/10.1128/JVI.05119-11.
13. Sonavane S, Chakrabarti P. 2008. Cavities and atomic packing in protein structures and interfaces. PLoS Comput. Biol. 4(9):e1000188. http://dx.doi.org/10.1371/journal.pcbi.1000188.
14. Hubbard SJ, Argos P. 1994. Cavities and packing at protein interfaces. Protein Sci. 3:2194-2206. http://dx.doi.org/10.1002/pro.5560031205.
15. Borgo B, Havranek JJ. 2012. Automated selection of stabilizing mutations in designed and natural proteins. Proc. Natl. Acad. Sci. U. S. A. 109:1494-1499. http://dx.doi.org/10.1073/pnas.1115172109.
16. Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS. 2010. Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res. 88:107-115. http://dx.doi.org/10.1016/j.antiviral.2010.08.004.
17. Chen W, Zhu Z, Feng Y, Dimitrov DS. 2008. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc. Natl. Acad. Sci. U. S. A. 105:17121-17126. http://dx.doi.org/10.1073/pnas.0805297105.
18. Meyerson JR, Tran EE, Kuybeda O, Chen W, Dimitrov DS, Gorlani A, Verrips T, Lifson JD, Subramaniam S. 2013. Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. Proc. Natl. Acad. Sci. U. S. A. 110:513-518. http://dx.doi.org/10.1073/pnas.121480110.
19. Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, Feng Y, Middleton D, Wang LF, Broder CC, Dimitrov DS. 2008. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J. Infect. Dis. 197:846-853. http://dx.doi.org/10.1086/528801.
20. Feng Y, Shen J, Streaker ED, Lockwood M, Zhu Z, Low PS, Dimitrov DS. 2011. A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res. Ther. 13: R59. http://dx.doi.org/10.1186/ar3312.
21. Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, Vanleeuwen S, Alam SM, McAdams M, Weaver EA, Camacho Z, Ma BJ, Li Y, Decker JM, Nabel GJ, Montefiori DC, Hahn BH, Korber BT, Gao F, Haynes BF. 2006. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353:268-282. http://dx.doi.org/10.1016/j.virol.2006.04.043.
22. Ho BK, Gruswitz F. 2008. Hollow: generating accurate representations of channel and interior surfaces in molecular structures. BMC Struct. Biol. 8:49. http://dx.doi.org/10.1186/1472-6807-8-49.
23. Tsai J, Gerstein M. 2002. Calculations of protein volumes: sensitivity analysis and parameter database. Bioinformatics 18:985-995. http://dx.doi.org/10.1093/bioinformatics/18.7.985.
24. Topham CM, Srinivasan N, Blundell TL. 1997. Prediction of the stability of protein mutants based on structural environment-dependent amino acid substitution and propensity tables. Protein Eng. 10:7-21. http://dx.doi.org/10.1093/protein/10.1.7.
25. Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS. 2008. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J. Mol. Biol. 382:779-789. http://dx.doi.org/10.1016/j.jmb.2008.07.054.
26. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS. 2006. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol. Cancer Ther. 5:114-120. http://dx.doi.org/10.1158/1535-7163.MCT-05-0252.
27. Chen W, Zhu Z, Feng Y, Dimitrov DS. 2010. A large human domain antibody library combining heavy and light chain CDR3 diversity. Mol. Immunol. 47:912-921. http://dx.doi.org/10.1016/j.molimm.2009.09.039.
28. Chen W, Feng Y, Zhao Q, Zhu Z, Dimitrov DS. 2012. Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics. Mol. Cancer Ther. 11:1400-1410. http://dx.doi.org/10.1158/1535-7163.MCT-12-0172.
29. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS. 2009. Engineered human antibody constant domains with increased stability. J. Biol. Chem. 284:14203-14210. http://dx.doi.org/10.1074/jbc.M900769200.
30. Brown BK, Wieczorek L, Sanders-Buell E, Rosa Borges A, Robb ML, Birx DL, Michael NL, McCutchan FE, Polonis VR. 2008. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375:529-538. http://dx.doi.org/10.1016/j.virol.2008.02.022.
31. Yao X, Chong H, Zhang C, Waltersperger S, Wang M, Cui S, He Y. 2012. Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J. Biol. Chem. 287:6788-6796. http://dx.doi.org/10.1074/jbc.M111.317883.
32. Shang H, Han X, Shi X, Zuo T, Goldin M, Chen D, Han B, Sun W, Wu H, Wang X, Zhang L. 2011. Genetic and neutralization sensitivity of diverse HIV-1 Env clones from chronically infected patients in China. J. Biol. Chem. 286:14531-14541. http://dx.doi.org/10.1074/jbc.M111.224527.
33. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, Conway JA, Wieczorek L, Brown B, Polonis V, West JT, Montefiori DC, Kappes JC, Ochsenbauer C. 2010. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1-13. http://dx.doi.org/10.1016/j.virol.2010.08.028.
34. Choudhry V, Zhang MY, Harris I, Sidorov IA, Vu B, Dimitrov AS, Fouts T, Dimitrov DS. 2006. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem. Biophys. Res. Commun. 348:1107-1115. http://dx.doi.org/10.1016/j.bbrc.2006.07.163.
35. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, III, Burton DR. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828.
36. Germain RN. 1997. T-cell signaling: the importance of receptor clustering. Curr. Biol. 7:R640-R644.
37. Sakihama T, Smolyar A, Reinherz EL. 1995. Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. Proc. Natl. Acad. Sci. U. S. A. 92:6444-6448.
38. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659. http://dx.doi.org/10.1038/31405.
39. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252. http://dx.doi.org/10.1128/JVI.78.23.13232-13252.2004.
40. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
41. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
42. Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BD, Grijsen ML, Prins JM, Schuitemaker H. 2011. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J. Virol. 85:7236-7245. http://dx.doi.org/10.1128/JVI.00196-11.
43. Bouvin-Pley M, Morgand M, Moreau A, Jestin P, Simonnet C, Tran L, Goujard C, Meyer L, Barin F, Braibant M. 2013. Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic. PLoS Pathog. 9(7):e1003477. http://dx.doi.org/10.1371/journal.ppat.1003477.
44. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steindl F, Jungbauer A, et al. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10:359-369. http://dx.doi.org/10.1089/aid.1994.10.359.
45. Arthos J, Cicala C, Steenbeke TD, Chun TW, Dela Cruz C, Hanback DB, Khazanie P, Nam D, Schuck P, Selig SM, Van Ryk D, Chaikin MA, Fauci AS. 2002. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J. Biol. Chem. 277:11456-11464. http://dx.doi.org/10.1074/jbc.M111191200.
46. Richards FM. 1974. The interpretation of protein structures: total volume, group volume distributions and packing density. J. Mol. Biol. 82:1-14.
47. Ishikawa K, Nakamura H, Morikawa K, Kanaya S. 1993. Stabilization of Escherichia coli ribonuclease HI by cavity-filling mutations within a hydrophobic core. Biochemistry 32:6171-6178. http://dx.doi.org/10.1021/bi00075a009.
48. Karpusas M, Baase WA, Matsumura M, Matthews BW. 1989. Hydrophobic packing in T4 lysozyme probed by cavity-filling mutants. Proc. Natl. Acad. Sci. U. S. A. 86:8237-8241.
49. Tanaka M, Chon H, Angkawidjaja C, Koga Y, Takano K, Kanaya S. 2010. Protein core adaptability: crystal structures of the cavity-filling variants of Escherichia coli RNase HI. Protein Pept. Lett. 17:1163-1169. http://dx.doi.org/10.2174/09298661079160342.
50. Wang JH, Meijers R, Xiong Y, Liu JH, Sakihama T, Zhang R, Joachimiak A, Reinherz EL. 2001. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class IIMHC molecule. Proc. Natl. Acad. Sci. U. S. A. 98:10799-10804. http://dx.doi.org/10.1073/pnas.191124098.
51. Yin Y, Wang XX, Mariuzza RA. 2012. Crystal structure of a complete ternary complex of T-cell receptor, peptide-MHC, and CD4. Proc. Natl. Acad. Sci. U. S. A. 109:5405-5410. http://dx.doi.org/10.1073/pnas.1118801109.
52. Ogata K, Kanei-Ishii C, Sasaki M, Hatanaka H, Nagadoi A, Enari M, Nakamura H, Nishimura Y, Ishii S, Sarai A. 1996. The cavity in the hydrophobic core of Myb DNA-binding domain is reserved for DNA recognition and trans-activation. Nat. Struct. Biol. 3:178-187.
53. Berger EA, Chaudhary VK, Clouse KA, Jaraquemada D, Nicholas JA, Rubino KL, Fitzgerald DJ, Pastan I, Moss B. 1990. Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions. AIDS Res. Hum. Retroviruses 6:795-804. http://dx.doi.org/10.1089/aid.1990.6.795.
54. Bugelski PJ, Thiem PA, Truneh A, Morgan DG. 1991. Recombinant human soluble CD4 does not inhibit immune function in cynomolgus monkeys. Toxicol. Pathol. 19:580-588.
55. Vita C, Drakopoulou E, Vizzavona J, Rochette S, Martin L, Menez A, Roumestand C, Yang YS, Ylisastigui L, Benjouad A, Gluckman JC. 1999. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 96:13091-13096.
56. Martin L, Stricher F, Misse D, Sironi F, Pugniere M, Barthe P, Prado-Gotor R, Freulon I, Magne X, Roumestand C, Menez A, Lusso P, Veas F, Vita C. 2003. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol. 21:71-76. http://dx.doi.org/10.1038/nbt768.
57. Stricher F, Huang CC, Descours A, Duquesnoy S, Combes O, Decker JM, Kwon YD, Lusso P, Shaw GM, Vita C, Kwong PD, Martin L. 2008. Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein. J. Mol. Biol. 382:510-524. http://dx.doi.org/10.1016/j.jmb.2008.06.069.
58. Acharya P, Luongo TS, Louder MK, McKee K, Yang Y, Do Kwon Y, Mascola JR, Kessler P, Martin L, Kwong PD. 2013. Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1. Structure 21:1018-1029. http://dx.doi.org/10.1016/j.str.2013.04.015.
59. Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK. 2005. Identification of N-phenyl-N'-(2,2,6,6-tetramethylpiperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339:213-225. http://dx.doi.org/10.1016/j.virol.2005.06.008.
60. Krummel MF, Sjaastad MD, Wulfing C, Davis MM. 2000. Differential clustering of CD4 and CD3ζ during T cell recognition. Science 289:1349-13452. http://dx.doi.org/10.1126/science.289.5483.1349.
61. Singer II, Scott S, Kawka DW, Chin J, Daugherty BL, DeMartino JA, DiSalvo J, Gould SL, Lineberger JE, Malkowitz L, Miller MD, Mitnaul L, Siciliano SJ, Staruch MJ, Williams HR, Zweerink HJ, Springer MS. 2001. CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J. Virol. 75:3779-3790. http://dx.doi.org/10.1128/JVI.75.8.3779-3790.2001.
62. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. 2004. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J. Exp. Med. 199:283-293. http://dx.doi.org/10.1084/jem.20030648.
63. Earl LA, Lifson JD, Subramaniam S. 2013. Catching HIV 'in the act' with 3D electron microscopy. Trends Microbiol. 21:397-404. http://dx.doi.org/10.1016/j.tim.2013.06.004.
64. Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, Trkola A. 2012. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 8(4):e1002634. http://dx.doi.org/10.1371/journal.ppat.1002634.
65. Bennett A, Liu J, Van Ryk D, Bliss D, Arthos J, Henderson RM, Subramaniam S. 2007. Cryoelectron tomographic analysis of an HIV-neutralizing protein and its complex with native viral gp120. J. Biol. Chem. 282:27754-27759. http://dx.doi.org/10.1074.jbc.M702025200.
66. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682. http://dx.doi.org/10.1038/nature01188.
67. Sievers EL, Senter PD. 2013. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64:15-29. http://dx.doi.org/10.1146/annurev-med-050311-201823.
68. Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. 2011. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin. Biol. Ther. 11:843-853. http://dx.doi.org/10.1517/14712598.2011.572874.
69. Turtle CJ, Hudecek M, Jensen MC, Riddell SR. 2012. Engineered T cells for anti-cancer therapy. Curr. Opin. Immunol. 24:633-639. http://dx.doi.org/10.1016/j.coi.2012.06.004.
70. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U. S. A. 103:4005-4010. http://dx.doi.org/10.1073/pnas.0508123103.
71. Chen W, Ying T, Dimitrov DS. 2013. Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. Expert Opin. Biol. Ther. 13:657-671. http://dx.doi.org/10.1517/14712598.2013.761969.